bluebird bio, Inc. (NASDAQ:BLUE)

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.

bluebird bio, Inc. (NASDAQ:BLUE)’s Financial Overview

bluebird bio, Inc. (NASDAQ:BLUE) declined -6.29% yesterday to close its trading session at $60.35. The company has 1 year Price Target of $76.86. bluebird bio, Inc. has 52-Week high of $83.94 and 52-Week Low of $35.37. The stock touched its 52-Week High on Dec 4, 2015 and 52-Week Low on May 12, 2016. The stock traded with the volume of 1.88 Million shares yesterday. The firm shows the market capitalization of $2.25 Billion.

bluebird bio, Inc. (NASDAQ:BLUE) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $-2.07/share against the analyst consensus estimate of $-1.59/share. The difference between the actual and expected EPS is $-0.48 a share with a surprise factor of -30.2%.

The firm is trading with SMA20 of 7.93 Percent, SMA50 of 0.13 Percent and SMA200 of 18.04 percent. bluebird bio, Inc. has P/S value of 369.03 while its P/B value stands at 3.23. Similarly, the company has Return on Assets of -24.9 percent, Return on Equity of -30.8 percent and Return on Investment of -18.5 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.

Many brokerage firms are involved in issuing their ratings on bluebird bio, Inc. (NASDAQ:BLUE). On 14-Oct-16 Cantor Fitzgerald Downgrade bluebird bio, Inc. Stock  to Sell. Another firm also rated the stock on 3-Jun-16 where Cantor Fitzgerald Initiated the stock to Hold.

The Stock currently has Analyst’ mean Recommendation of 1.9 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 15 analysts offering 12-month price forecasts for bluebird bio Inc have a median target of 80.00, with a high estimate of 132.00 and a low estimate of 37.00. The median estimate represents a +32.56% increase from the last price of 60.35.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

BB&T Corporation (NYSE:BBT)

BB&T Corporation is a multi-bank holding company. The company offers full-service commercial and retail banking and additional financial services such as insurance, corporate finance, international banking, leasing and trust. BB&T conducts its operations in North Carolina, South Carolina, Virginia, Maryland, Georgia, West Virginia, Kentucky and the metropolitan Washington, D.C. area.

BB&T Corporation (NYSE:BBT)’s Financial Outlook

The 26 analysts offering 12-month price forecasts for BB&T Corp have a median target of 41.50, with a high estimate of 47.00 and a low estimate of 36.00. The median estimate represents a -8.29% decrease from the last price of 45.25.

BB&T Corporation is estimated to report earnings on  01/19/2017. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 14 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.73.  The reported EPS for the same quarter last year was $0.68.

According to Zacks Investment Research, BB&T Corporation has a Consensus Recommendation of 2.53. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock gained 2.49% and closed its last trading session at $45.25. The company has the market capitalization of $36.72 Billion. The stock has 52-week high of $45.31 and 52-Week low of $29.95. The firm touched its 52-Week high on Nov 30, 2016 and 52-Week low on Feb 11, 2016. The company has volume of 6.95 Million shares. The company has a total of 811.42 Million shares outstanding.

BB&T Corporation (NYSE:BBT) in the last quarter reported its actual EPS of $0.73/share where the analyst estimated EPS was $0.7/share. The difference between the actual and Estimated EPS is $0.03. This shows a surprise factor of 4.3 percent.

The company has YTD performance of 23.61 percent. Beta for BB&T Corporation stands at 1.06 while its ATR (average true range) is 0.74. The company has Weekly Volatility of 1.05%% and Monthly Volatility of 1.82%%.

BB&T Corporation has distance from 20-day Simple Moving Average (SMA20) of 7.9%, Distance from 50-Day Simple Moving Average of 14.23 percent and Distance from 200-Day Simple Moving Average of 25.49%.

The Company currently has ROA (Return on Assets) of 1 percent, Return on Equity (ROE) of 8.4 Percent and Return on Investment (ROI) of 9% with Gross margin of 0 percent and Operating & Profit margin of 81.1% and 30.9% respectively.